Hikma Pharmaceuticals Plc Company Profile (LON:HIK)

About Hikma Pharmaceuticals Plc (LON:HIK)

Hikma Pharmaceuticals Plc logoHikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 260 products in approximately 110 different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: LON:HIK
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: £4.03 billion
  • Outstanding Shares: 240,959,000
Average Prices:
  • 50 Day Moving Avg: GBX 1,866.09
  • 200 Day Moving Avg: GBX 1,888.75
  • 52 Week Range: GBX 1,573 - GBX 2,703
P/E:
  • Trailing P/E Ratio: 25.17
  • P/E Growth: 0.93
Sales & Book Value:
  • Annual Revenue: £1.95 billion
  • Price / Sales: 2.06
  • Book Value: GBX 9.94 per share
  • Price / Book: 1.68
Dividend:
  • Dividend Yield: 0.9%
Profitability:
  • EBIDTA: £446 million
Misc:
  • Average Volume: 845,563 shs.
 

Frequently Asked Questions for Hikma Pharmaceuticals Plc (LON:HIK)

What is Hikma Pharmaceuticals Plc's stock symbol?

Hikma Pharmaceuticals Plc trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How often does Hikma Pharmaceuticals Plc pay dividends? What is the dividend yield for Hikma Pharmaceuticals Plc?

Hikma Pharmaceuticals Plc announced a dividend on Wednesday, March 15th. Stockholders of record on Thursday, April 6th will be paid a dividend of GBX 0.22 per share on Thursday, May 25th. This represents a dividend yield of 0.78%. The ex-dividend date is Thursday, April 6th. This is a positive change from Hikma Pharmaceuticals Plc's previous dividend of $0.21. The official announcement can be accessed at this link. View Hikma Pharmaceuticals Plc's Dividend History.

Where is Hikma Pharmaceuticals Plc's stock going? Where will Hikma Pharmaceuticals Plc's stock price be in 2017?

10 brokerages have issued 1-year price objectives for Hikma Pharmaceuticals Plc's stock. Their predictions range from GBX 1,450 to GBX 2,900. On average, they expect Hikma Pharmaceuticals Plc's stock price to reach GBX 2,177.10 in the next twelve months. View Analyst Ratings for Hikma Pharmaceuticals Plc.

Who are some of Hikma Pharmaceuticals Plc's key competitors?

How do I buy Hikma Pharmaceuticals Plc stock?

Shares of Hikma Pharmaceuticals Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How much does a share of Hikma Pharmaceuticals Plc stock cost?

One share of Hikma Pharmaceuticals Plc stock can currently be purchased for approximately GBX 1,671.

Analyst Ratings

Consensus Ratings for Hikma Pharmaceuticals Plc (LON:HIK) (?)
Ratings Breakdown: 2 Sell Ratings, 3 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.30)
Consensus Price Target: GBX 2,177.10

Analysts' Ratings History for Hikma Pharmaceuticals Plc (LON:HIK)
Show:
DateFirmActionRatingPrice TargetDetails
5/22/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,800 -> GBX 1,500View Rating Details
5/19/2017Numis Securities LtdReiterated RatingAddGBX 2,000View Rating Details
5/17/2017Jefferies Group LLCDowngradeUnderperformGBX 2,162 -> GBX 1,450View Rating Details
5/5/2017HSBC Holdings plcReiterated RatingReduceGBX 1,800View Rating Details
4/4/2017Stifel NicolausReiterated RatingBuyGBX 2,550View Rating Details
3/30/2017Peel HuntReiterated RatingBuyView Rating Details
11/30/2016AlphaValueReiterated RatingBuyGBX 2,431View Rating Details
11/16/2016Citigroup IncReiterated RatingNeutralView Rating Details
11/15/2016Morgan StanleyUpgradeEqual Weight -> OverweightGBX 2,500 -> GBX 2,200View Rating Details
9/9/2016Barclays PLCReiterated RatingOverweightGBX 2,900View Rating Details
3/16/2016Panmure GordonUpgradeBuyGBX 2,120View Rating Details
9/15/2015Goldman Sachs Group IncReiterated RatingBuyView Rating Details
9/2/2015Shore CapitalUpgradeBuyView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Hikma Pharmaceuticals Plc (LON:HIK)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Hikma Pharmaceuticals Plc (LON:HIK)
Current Year EPS Consensus Estimate: $1.19 EPS

Dividends

Dividend History by Quarter for Hikma Pharmaceuticals Plc (LON:HIK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/15/2017€0.220.78%4/6/20174/6/20175/25/2017
3/11/2015€0.210.64%4/16/20154/16/20155/21/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Hikma Pharmaceuticals Plc (LON:HIK)
Insider Trades by Quarter for Hikma Pharmaceuticals Plc (LON:HIK)
Insider Trades by Quarter for Hikma Pharmaceuticals Plc (LON:HIK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/19/2016Ali Al-HusryInsiderBuy50,000GBX 1,790£895,000
12/16/2016Mazen DarwazahInsiderBuy90,730GBX 1,849£1,677,597.70
12/12/2016Ali Al-HusryInsiderBuy50,000GBX 1,707£853,500
12/9/2016Ali Al-HusryInsiderBuy50,000GBX 1,723£861,500
12/6/2016Ali Al-HusryInsiderBuy100,000GBX 1,682£1,682,000
12/5/2016Ali Al-HusryInsiderBuy50,000GBX 1,674£837,000
12/2/2016Mazen DarwazahInsiderBuy50,000GBX 1,662£831,000
12/1/2016Mazen DarwazahInsiderBuy50,000GBX 1,674£837,000
11/30/2016Said DarwazahInsiderBuy50,000GBX 1,662£831,000
9/28/2016Said DarwazahInsiderBuy10,000GBX 2,085£208,500
9/27/2016Ali Al-HusryInsiderBuy50,000GBX 2,094£1,047,000
9/26/2016Said DarwazahInsiderBuy50,000GBX 2,078£1,039,000
9/23/2016Ali Al-HusryInsiderBuy50,000GBX 2,099£1,049,500
9/21/2016Ali Al-HusryInsiderBuy50,000GBX 2,138£1,069,000
9/16/2016Al-Husry,AliInsiderBuy50,000GBX 2,119£1,059,500
9/15/2016Darwazah,SaidInsiderBuy70,251GBX 2,122£1,490,726.22
9/8/2016Darwazah,MazenInsiderBuy150,000GBX 2,162£3,243,000
9/6/2016Darwazah,MazenInsiderBuy155,991GBX 2,194£3,422,442.54
8/31/2016Al-Husry,AliInsiderBuy140,000GBX 2,150£3,010,000
8/26/2016Darwazah,SaidInsiderBuy200,000GBX 2,160£4,320,000
6/24/2016Darwazah,MazenInsiderBuy150,000GBX 2,200£3,300,000
6/17/2016Al-Husry,AliInsiderBuy70,000GBX 22£15,400
5/9/2016Darwazah,SaidInsiderBuy17,440GBX 2,228£388,563.20
4/26/2016Darwazah,SaidInsiderBuy10,000GBX 2,260£226,000
4/25/2016Darwazah,SaidInsiderBuy10,000GBX 2,324£232,400
4/22/2016Darwazah,SaidInsiderBuy30,000GBX 2,325£697,500
4/20/2016Darwazah,SaidInsiderBuy30,000GBX 2,271£681,300
4/19/2016Darwazah,SaidInsiderBuy30,000GBX 2,266£679,800
4/11/2016J. Castellani,JohnInsiderBuy2,500GBX 2,103£52,575
4/7/2016Darwazah,MazenInsiderBuy60,000GBX 2,118£1,270,800
4/5/2016Darwazah,SaidInsiderBuy30,000GBX 2,055£616,500
3/31/2016Darwazah,SaidInsiderBuy30,000GBX 1,972£591,600
3/24/2016Butler,PatInsiderBuy2,500GBX 1,920£48,000
3/21/2016Pickering ,RobertInsiderBuy2,500GBX 1,856£46,400
8/27/2015Kirby,PamelaInsiderBuy3,317GBX 2,264£75,096.88
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Hikma Pharmaceuticals Plc (LON:HIK)
Latest Headlines for Hikma Pharmaceuticals Plc (LON:HIK)
Source:
DateHeadline
americanbankingnews.com logoJPMorgan Chase & Co. Reiterates "Neutral" Rating for Hikma Pharmaceuticals Plc (HIK)
www.americanbankingnews.com - May 22 at 7:00 PM
News IconUPDATE 1-UK Stocks-Factors to watch on May 19
www.businessinsider.com - May 20 at 9:58 AM
morningstar.co.uk logoTOP NEWS: Hikma Pharmaceuticals Trims Revenue Outlook On Generics
www.morningstar.co.uk - May 19 at 5:25 PM
rttnews.com logoHikma Pharmaceuticals Cuts FY Revenue Outlook
www.rttnews.com - May 19 at 5:25 PM
marketwatch.com logoHikma cuts revenue guidance for 2017
www.marketwatch.com - May 19 at 5:25 PM
thestreet.com logoHikma Trims Full Year Revenue Guidance After Advair Diskus Delay - TheStreet.com
www.thestreet.com - May 19 at 10:13 AM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Downgraded by Numis Securities Ltd to "Add"
www.americanbankingnews.com - May 19 at 9:00 AM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Downgraded by Jefferies Group LLC to "Underperform"
www.americanbankingnews.com - May 18 at 7:46 PM
americanbankingnews.com logoJPMorgan Chase & Co. Lowers Hikma Pharmaceuticals Plc (HIK) Price Target to GBX 1,800
www.americanbankingnews.com - May 12 at 9:32 PM
thestreet.com logoHikma Shares Plunge After It Says 'Low Likelihood' of 2017 Generic Advair Approval - TheStreet.com
www.thestreet.com - May 12 at 6:20 PM
finance.yahoo.com logoHikma Pharmaceuticals Plc : Undervalued relative to peers, but don’t ignore the other factors
finance.yahoo.com - May 12 at 6:20 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 12 at 7:40 AM
morningstar.co.uk logoTOP NEWS: Hikma Says Generic Advair Unlikely To Be Approved This Year
www.morningstar.co.uk - May 11 at 6:15 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Earns " Buy" Rating from Numis Securities Ltd
www.americanbankingnews.com - May 11 at 11:08 AM
finance.yahoo.com logoHikma Shares Plunge After It Says 'Low Likelihood' of 2017 Generic Advair Approval
finance.yahoo.com - May 11 at 4:19 AM
americanbankingnews.com logoHSBC Holdings plc Reiterates "Reduce" Rating for Hikma Pharmaceuticals Plc (HIK)
www.americanbankingnews.com - May 6 at 10:34 PM
nytimes.com logoTeva's New Asthma Inhaler Poses First Competition for GSK's Advair
www.nytimes.com - April 20 at 10:46 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 17 at 7:48 AM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Upgraded to "Buy" at Numis Securities Ltd
www.americanbankingnews.com - April 14 at 3:44 AM
americanbankingnews.com logoStifel Nicolaus Reiterates Buy Rating for Hikma Pharmaceuticals Plc (HIK)
www.americanbankingnews.com - April 8 at 6:08 PM
finance.yahoo.com logoHikma Pharmaceuticals Plc : HIK-GB: Dividend Analysis : April 07th, 2017 (record date) : By the numbers : April 7, 2017
finance.yahoo.com - April 7 at 10:36 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Stock Rating Reaffirmed by HSBC Holdings plc
www.americanbankingnews.com - April 7 at 6:20 PM
investopedia.com logoJazz Pharma Settles 2010 Xyrem Patent Lawsuit (JAZZ)
www.investopedia.com - April 7 at 10:15 AM
reuters.com logoBRIEF-Hikma enters into settlement agreement with Jazz
www.reuters.com - April 7 at 10:15 AM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Rating Reiterated by JPMorgan Chase & Co.
www.americanbankingnews.com - April 6 at 10:54 PM
bizjournals.com logoSigurdur (Siggi) Olafsson And Jason Grenfell-Gardner Nominated To Serve On Board Of Directors
www.bizjournals.com - April 3 at 2:20 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Earns Neutral Rating from JPMorgan Chase & Co.
www.americanbankingnews.com - April 3 at 5:34 AM
americanbankingnews.com logoHikma Pharmaceuticals Plc's (HIK) Neutral Rating Reiterated at JPMorgan Chase & Co.
www.americanbankingnews.com - April 1 at 12:25 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc's (HIK) "Buy" Rating Reiterated at Peel Hunt
www.americanbankingnews.com - March 31 at 8:01 PM
zacks.com logoMylan Receives CRL for Generic Advair Diskus From the FDA
www.zacks.com - March 31 at 5:42 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Stock Rating Reaffirmed by Numis Securities Ltd
www.americanbankingnews.com - March 30 at 3:45 PM
News IconThe FDA just rejected Mylan's generic version of Advair
www.businessinsider.com - March 29 at 6:12 PM
americanbankingnews.com logoJPMorgan Chase & Co. Reaffirms Neutral Rating for Hikma Pharmaceuticals Plc (HIK)
www.americanbankingnews.com - March 25 at 12:57 AM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 21 at 12:52 PM
News IconUPDATE 1-Drugmaker Hikma's FY core operating profit rises 2.4 pct
www.businessinsider.com - March 16 at 8:47 PM
marketwatch.com logoHikma Pharma profit drops 39%, dividend raised
www.marketwatch.com - March 15 at 10:59 PM
reuters.com logoDrugmaker Hikma's full-year core operating profit rises 2.4 pct
www.reuters.com - March 15 at 5:59 PM
bizjournals.com logoWest-Ward Columbus misses 2016 sales projections, 2017 hopes tied to generic Advair
www.bizjournals.com - March 15 at 5:59 PM
seekingalpha.com logoHikma Pharmaceuticals plc. 2016 Q4 - Results - Earnings Call Slides
seekingalpha.com - March 15 at 5:59 PM
uk.finance.yahoo.com logoResources stock rally drives European shares to 2-week closing high
uk.finance.yahoo.com - March 15 at 5:59 PM
finance.yahoo.com logoEdited Transcript of HIK.L earnings conference call or presentation 15-Mar-17 9:30am GMT
finance.yahoo.com - March 15 at 5:59 PM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 14 at 2:14 AM
uk.finance.yahoo.com logo2 FTSE 100 growth stocks to buy before it’s too late?
uk.finance.yahoo.com - March 13 at 11:06 AM
americanbankingnews.com logoHikma Pharmaceuticals Plc (HIK) Rating Lowered to Add at Numis Securities Ltd
www.americanbankingnews.com - March 10 at 11:10 PM
morningstar.co.uk logoHikma Pharmaceuticals Launches Generic Version Of Pristiq In US
www.morningstar.co.uk - March 10 at 10:12 AM
bloomberg.com logoEuropean Stocks Decline as Trump Tweet Drags Drugmakers Lower
www.bloomberg.com - March 7 at 5:24 PM
finance.yahoo.com logoAvadel Pharmaceuticals (AVDL) Looks Good: Stock Up 5.3%
finance.yahoo.com - February 24 at 10:41 AM
reuters.com logoBRIEF-Hikma signs licensing deal with Orion for asthma product
www.reuters.com - February 13 at 11:30 AM
finance.yahoo.com logoPropeller Health Enters into Collaboration to Connect Breezhaler™ Devices to the Propeller Platform
finance.yahoo.com - February 8 at 6:20 PM
uk.finance.yahoo.com logoWeak pound buoys GSK but drugmaker warns on 2017 generic threat
uk.finance.yahoo.com - February 8 at 6:20 PM

Social

Social activity is not available for this stock.

Chart

Hikma Pharmaceuticals Plc (HIK) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff